全球單株抗體治療市場規模、佔有率和成長分析：按類型、按應用分類 - 產業預測（2023-2030）

Global Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Type(Murine Antibodies, Chimeric Antibodies), By Application(Oncology, Autoimmune Diseases) - Industry Forecast 2023-2030

出版日期: 2023年10月09日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2021年全球單株抗體治療市場規模為1,338億美元，預計將從2022年的1,435.7億美元增加到2030年的2,522.6億美元，年複合成長率預計為7.3%。

市場的主要驅動力之一是癌症、自體免疫疾病和心血管疾病等慢性疾病的流行。單株抗體療法在治療這些疾病方面已顯示出有希望的結果，並且越來越多的採用。此外，高齡化和文明病的增加也進一步促進了市場的成長。技術的進步使得高度特異性和有效的抗體的生產成為可能，從而提高了治療效果。此外，對個人化醫療和標靶治療的日益關注進一步推動了對單株抗體治療的需求。

全球單株抗體治療市場動態

全球單株抗體治療市場的促進因素

生物技術和基因工程的進展

生物技術和基因工程的重大進步在先進單株抗體治療的開發中發揮關鍵作用。這些進步促進了抗體的生產，提高了特異性、功效並減少了副作用。基因工程等技術使研究人員能夠針對特定標靶最佳化單株抗體，從而提高其治療潛力。這些突破正在擴大單株抗體的應用範圍並提高其治療的成功率。

全球單株抗體治療市場的抑制因素

可能的副作用和安全性問題

與任何醫療介入一樣，單株抗體治療可能會產生副作用和安全性問題。有些患者可能會出現藥物相關反應，包括輸液相關反應。此外，還存在潛在的免疫抗原性，即患者的免疫系統對治療產生免疫反應。當治療藥物與體內非預期目標相互作用時，也可能發生脫靶效應。密切監測和解決這些安全問題對於確保患者健康、維持治療信心和遵守法規標準至關重要。持續監控、穩健的安全評估以及潛在風險的清晰溝通對於有效管理這些問題至關重要。

全球單株抗體治療的趨勢

擴大採用和開發個體化和標靶治療：單株抗體療法在治療多種疾病（包括癌症、自體免疫疾病和感染疾病）方面正在獲得顯著的發展勢頭。伴隨診斷、基因分析和生物標記識別等個人化醫療方法正在被整合到單株抗體治療的開發和發展中。這種趨勢允許更精確和客製化的治療方法，最大限度地提高治療效果，同時最大限度地減少副作用。

本報告針對全球單株抗體治療市場進行研究分析，提供市場動態與前景、細分分析、公司簡介等。

Roche Holding AG (Switzerland)
Johnson & Johnson (US)
Novartis International AG (Switzerland)
Pfizer Inc. (US)
Merck & Co., Inc. (US)
Amgen Inc. (US)
AstraZeneca PLC (UK)
Bristol Myers Squibb Company (US)
AbbVie Inc. (US)
Eli Lilly and Company (US)
Sanofi SA (France)
GlaxoSmithKline plc (UK)
Takeda Pharmaceutical Company Limited (Japan)
Biogen Inc. (US)
Regeneron Pharmaceuticals, Inc. (US)
Moderna, Inc. (US)
BioNTech SE (Germany)
Alexion Pharmaceuticals, Inc. (US)
Gilead Sciences, Inc. (US)
CSL Limited (Australia)

簡介目錄

Product Code: SQMIG35A2527

Global Monoclonal Antibody Therapy Market size was valued at USD 133.8 billion in 2021 and is poised to grow from USD 143.57 billion in 2022 to USD 252.26 billion by 2030, growing at a CAGR of 7.3% in the forecast period (2023-2030).

One of the primary drivers of the global monoclonal antibody therapy market is the increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and cardiovascular diseases. Monoclonal antibody therapies have shown promising results in the treatment of these conditions, leading to their growing adoption. Additionally, the aging population and the rise in lifestyle-related diseases have further contributed to the market growth. Technological advancements have enabled the production of highly specific and effective antibodies, increasing their therapeutic efficacy. Additionally, the growing focus on personalized medicine and targeted therapies has further fueled the demand for monoclonal antibody therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Monoclonal Antibody Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibody Therapy Market Segmental Analysis

The global monoclonal antibody therapy market is segmented based on type, application, and region. Based on type, the market can be segmented into Murine Antibodies, Chimeric Antibodies, Humanised Antibodies, and Fully Human Antibodies. Based on application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Monoclonal Antibody Therapy Market Dynamics

Drivers of the Global Monoclonal Antibody Therapy Market

Advancements in Biotechnology and Genetic Engineering

Significant progress in biotechnology and genetic engineering has played a pivotal role in the development of advanced monoclonal antibody therapies. These advancements have facilitated the engineering of antibodies with improved specificity, efficacy, and reduced side effects. Through techniques such as genetic manipulation, researchers can optimise monoclonal antibodies for specific targets, enhancing their therapeutic potential. These breakthroughs have broadened the range of applications for monoclonal antibody therapies and increased their success rates.

Restraints in the Global Monoclonal Antibody Therapy Market

Potential Side Effects and Safety Concerns

Like any medical intervention, monoclonal antibody therapies carry the potential for side effects and safety concerns. Some patients may experience reactions related to the administration of the therapy, such as infusion-related reactions. Additionally, there is a possibility of immunogenicity, where the patient's immune system may mount an immune response against the therapy. Off-target effects, where the therapy may interact with unintended targets in the body, can also occur. It is crucial to closely monitor and address these safety concerns to ensure patient well-being, maintain confidence in the therapy, and adhere to regulatory standards. Continuous monitoring, robust safety assessment, and clear communication of potential risks are vital in managing these concerns effectively.

Market Trends of Global Monoclonal Antibody Therapy Key

Increasing Adoption and Development of Personalised and Targeted Therapies: Monoclonal antibody therapies have gained significant momentum in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Personalised medicine approaches, such as companion diagnostics, genetic profiling, and biomarker identification, are being integrated into the development and prescription of monoclonal antibody therapies. This trend allows for a more precise and tailored treatment approach, maximising therapeutic efficacy while minimising adverse effects.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Monoclonal Antibody Therapy Market by Type
- Market Overview
- Murine Antibodies
- Chimeric Antibodies
- Humanised Antibodies and Fully Human Antibodies
Global Monoclonal Antibody Therapy Market by Application
- Market Overview
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Inflammatory Conditions and Others.
Global Monoclonal Antibody Therapy Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Roche Holding AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Johnson & Johnson (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis International AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pfizer Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Merck & Co., Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Amgen Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AstraZeneca PLC (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bristol Myers Squibb Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AbbVie Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eli Lilly and Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sanofi S.A. (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- GlaxoSmithKline plc (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Biogen Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Regeneron Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Moderna, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- BioNTech SE (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Alexion Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Gilead Sciences, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- CSL Limited (Australia)
Company Overview
Business Segment Overview
Financial Updates
Key Developments